Skip to main content
. Author manuscript; available in PMC: 2011 Jan 1.
Published in final edited form as: Clin Sci (Lond). 2010 Aug 5;119(10):407–421. doi: 10.1042/CS20100094

Figure 3. Overview of LDL metabolism in humans.

Figure 3

Dietary cholesterol and triacylglycerols are packaged with apolipoproteins in the enterocytes of the small intestine and secreted into the lymphatic system as chylomicrons (CM). As chylomicrons circulate, the core triacylglycerols are hydrolysed by LpL, resulting in the formation of chylomicron remnants (CM Rem), which are rapidly removed by the liver. Dietary cholesterol has four possible fates once it reaches the liver: it can be (i) esterified and stored as cholesteryl esters in hepatocytes; (ii) packaged into VLDL particles and secreted into the plasma; (iii) secreted directly into the bile; or (iv) converted into bile acids and secreted into the bile. VLDL particles secreted into the plasma undergo lipolysis to form VLDL remnants (VLDL Rem). Approx. 50 % of VLDL remnants are removed by the liver via the LDLR and the remainder mature into LDL, the major cholesterol transport particle in the blood. An estimated 70 % of circulating LDL is cleared by LDLR in the liver. ABCG5 and ABCG8 (ABC family G, members 5 and 8 respectively) are located predominantly in the enterocytes of the duodenum and jejunum, the sites of uptake of dietary sterols, and in hepatocytes, where they participate in sterol trafficking into bile. ApoB, apolipoprotein B; ARH, autosomal recessive hypercholesterolaemia protein; FFA, non-esterified (‘free’) fatty acid Journal of Clinical Investigation. Online by Rader, D.J., Cohen, J. and Hobbs, H.H. Copyright 2003 by American Society for Clinical Investigation. Reproduced with permission of American Society for Clinical Investigation in the format Journal via Copyright Clearance Center.